非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系

摘要

目的 探讨晚期非小细胞肺癌(NSCLC)组织中β-微管蛋白Ⅲ(β-tubulinⅢ)的表达及其与含紫杉醇方案耐药的关系.方法 经病理学确诊为ⅢB～Ⅳ期的120例NSCLC患者随机分为2组,试验组60例给予紫杉醇/顺铂(TP)方案,对照组60例给予长春瑞滨/顺铂(NP)方案,2个周期后评价疗效.应用免疫组化法检测120例NSCLC组织中β-tubulinⅢ的表达并分析其与含紫杉醇方案耐药的关系.结果 NSCLC组织中β-tubulinⅢ表达水平与患者年龄、性别、分期及组织学类型无关.β-tubulinⅢ高表达与TP方案化疗耐药有关:TP方案化疗耐药者β-tubulinⅢ的高表达率为77.3％,明显高于敏感者的42.1％.β-tubulinⅢ高表达与NP方案化疗耐药无关.结论 β-tubulinⅢ在NSCLC组织中的表达水平与含紫杉醇方案耐药有关.%Objective To determine the relationship between the expression of β-tubulin M and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer ( NSCLC ). Methods A total of 120 NSCLC patients were randomly divided into two groups. The treatment group (60 cases) was treated with TP regimen, the control group (60 cases) with NP regimen. All patients had received 2 cycles chemotherapy. The β-tubulin Ⅲ expression of 108 NSCLC patients were examined via immunohistochemical method and the relationship between the β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance were analyzed. Results β-tubulin Ⅲ expression level did not show any association with patient age, sex, clinical stage and histology type. The expression of β-tubulin Ⅲ was associated with paclitaxel resistance in NSCLC. The high expression rate of β-tubulin Ⅲ in chemo-resistant patients was 77.3% , and that of chemo-sensitive patients was 42.1% . The expression of β-tubulin Ⅲ was not associated with vinorelbine resistance in NSCLC. Conclusion The expression of β-tubulin Ⅲ in NSCLC is related to paclitaxel-containing regimen resistance, which shows predictive value to chemoresistance in NSCLC.